AIM IMMUNOTECH INC. Impairment of Intangible Assets, Finite-lived
AIM IMMUNOTECH INC. (AIM) reported Impairment of Intangible Assets, Finite-lived of $24.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsFinitelived · last filed 2026-08-07
- AIM IMMUNOTECH INC. impairment of intangible assets, finite-lived for the quarter ending 2025-12-31 was $441.00K, a 21950.00% increase year-over-year.
- AIM IMMUNOTECH INC. impairment of intangible assets, finite-lived for the quarter ending 2025-09-30 was $82.00K.
- AIM IMMUNOTECH INC. impairment of intangible assets, finite-lived for the quarter ending 2025-06-30 was $280.00K.
- AIM IMMUNOTECH INC. impairment of intangible assets, finite-lived for the quarter ending 2025-03-31 was $335.00K.
- AIM IMMUNOTECH INC. impairment of intangible assets, finite-lived for fiscal 2025 was $1.14M, a 2270.83% increase from fiscal 2024.
- AIM IMMUNOTECH INC. impairment of intangible assets, finite-lived for fiscal 2024 was $48.00K.
- AIM IMMUNOTECH INC. impairment of intangible assets, finite-lived for fiscal 2020 was $158.00K.
| Period end | Impairment of Intangible Assets, Finite-lived 3 month | Impairment of Intangible Assets, Finite-lived 6 month | Impairment of Intangible Assets, Finite-lived 9 month | Impairment of Intangible Assets, Finite-lived 12 month |
|---|---|---|---|---|
| 2026-06-30 | $24.00K 10-Q · filed 2026-08-07 | |||
| 2025-12-31 | $441.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $523.00K derived: sum of 2 quarters · filed 2026-03-27 | $803.00K derived: sum of 3 quarters · filed 2026-08-07 | $1.14M 10-K · filed 2026-03-27 |
| 2025-09-30 | $82.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-17 | $362.00K derived: sum of 2 quarters · filed 2026-08-07 | $697.00K 10-Q · filed 2025-11-17 | $699.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $280.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $615.00K 10-Q · filed 2026-08-07 | $617.00K derived: sum of 3 quarters · filed 2026-08-07 | |
| 2025-03-31 | $335.00K 10-Q · filed 2026-05-15 | $337.00K derived: sum of 2 quarters · filed 2026-05-15 | ||
| 2024-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $48.00K 10-K · filed 2026-03-27 | ||
| 2024-09-30 | $46.00K 10-Q · filed 2025-11-17 | |||
| 2020-12-31 | $158.00K 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Silexion Therapeutics Corp (SLXN) | $0.001B |